How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

289 results for

Non-Sulfonylurea Insulin Secretagogues

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Non-Sulfonylurea Insulin Secretagogues

Non-Sulfonylurea Insulin Secretagogues Non-Sulfonylurea Insulin Secretagogues Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Non (...) -Sulfonylurea Insulin Secretagogues Non-Sulfonylurea Insulin Secretagogues Aka: Non-Sulfonylurea Insulin Secretagogues , Meglitinide , Repaglinide , Prandin , Nateglinide , Starlix From Related Chapters II. Mechanism secretogogue III. Indication Early Oral Agent Elevated postprandial Consider if only used intermittently pre-meal IV. Contraindications to sulfa V. Category VI. Mechanism Benzoic acid derivative Similar to Binds different sites from s Closes ATP sensitive K+ channels Results in secretion

2018 FP Notebook

2. β-Cell signalling and insulin secretagogues: A path for improved diabetes therapy. (PubMed)

β-Cell signalling and insulin secretagogues: A path for improved diabetes therapy. Insulin secretagogues including sulfonylureas, glinides and incretin-related drugs such as dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide-1 receptor agonists are widely used for treatment of type 2 diabetes. In addition, glucokinase activators and G-protein-coupled receptor 40 (GPR40) agonists also have been developed, although the drugs are not clinically usable. These different drugs exert (...) their effects on insulin secretion by different mechanisms. Recent advances in β-cell signalling studies have not only deepened our understanding of insulin secretion but also revealed novel mechanisms of insulin secretagogues. Clarification of the signalling mechanisms of the insulin secretagogues will contribute to improved drug therapy for diabetes.© 2017 John Wiley & Sons Ltd.

2017 obesity & metabolism

3. A Novel Diphenylthiosemicarbazide Is a Potential Insulin Secretagogue for Anti-Diabetic Agen. (PubMed)

A Novel Diphenylthiosemicarbazide Is a Potential Insulin Secretagogue for Anti-Diabetic Agen. Insulin secretagogues are used for treatment of type 2 diabetes. We attempted to discover novel small molecules to stimulate insulin secretion by using in silico similarity search using sulfonylureas as query, followed by measurement of insulin secretion. Among 38 compounds selected by in silico similarity search, we found three diphenylsemicarbazides and one quinolone that stimulate insulin secretion (...) . We focused on compound 8 (C8), which had the strongest insulin-secreting effect. Based on the structure-activity relationship of C8-derivatives, we identified diphenylthiosemicarbazide (DSC) 108 as the most potent secretagogue. DSC108 increased the intracellular Ca2+ level in MIN6-K8 cells. Competitive inhibition experiment and electrophysiological analysis revealed sulfonylurea receptor 1 (SUR1) to be the target of DSC108 and that this diphenylthiosemicarbazide directly inhibits ATP-sensitive K

Full Text available with Trip Pro

2016 PLoS ONE

4. Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?: A randomized controlled trial of a DPP4 inhibitor versus insulin secretagogues. (PubMed)

Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?: A randomized controlled trial of a DPP4 inhibitor versus insulin secretagogues. We conducted a pilot study to evaluate two therapeutic strategies at the time of insulin initiation in type 2 diabetic patients insufficiently controlled with metformin+insulin-secretagogues (IS, sulfonylureas or glinides). Patients were randomized to remain under the same dual therapy (...) or to receive metformin+DPP4 inhibitors while starting insulin. Similar glycemic control was achieved in both groups. However less hypoglycemia was observed with DPP4 inhibitors despite higher doses of insulin. Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

2016 Diabetes research and clinical practice

5. Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study. (PubMed)

), sulfonylureas, thiazolidinediones (TZDs), glucagon-like peptide 1 receptor agonists (GLP1 receptor agonists), dipeptidyl peptidase 4 inhibitors (DPP4 inhibitors), and sodium-glucose co-transporter inhibitors (SGLT2 inhibitors), among patients with type 2 diabetes initiating insulin. We used the 2010-2015 MarketScan Commercial Claims and Encounters data examining 72,971 patients with type 2 diabetes aged 18-65 years old who initiated insulin and had filled a prescription for a non-insulin diabetes medication (...) in the 90 days prior to insulin initiation. Our primary outcome was the proportion of patients refilling the various non-insulin diabetes medications during the first 90 days after insulin initiation. We also used time-to-event analysis to characterize the time to discontinuation of specific medication classes.Metformin was the most common non-insulin medication used prior to insulin initiation (N = 53,017, 72.7%), followed by sulfonylureas (N = 25,439, 34.9%) and DPP4 inhibitors (N = 8,540, 11.7

Full Text available with Trip Pro

2019 PLoS ONE

6. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. (PubMed)

Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. The projected rise in the incidence of type 2 diabetes mellitus (T2DM) could develop into a substantial health problem worldwide. Whether insulin secretagogues (sulphonylureas and meglitinide analogues) are able to prevent or delay T2DM and its associated complications in people at risk for the development (...) of T2DM is unknown.To assess the effects of insulin secretagogues on the prevention or delay of T2DM and its associated complications in people with impaired glucose tolerance, impaired fasting blood glucose, moderately elevated glycosylated haemoglobin A1c (HbA1c) or any combination of these.We searched the Cochrane Central Register of Controlled Trials, MEDLINE, PubMed, Embase, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform, and the reference lists

Full Text available with Trip Pro

2016 The Cochrane database of systematic reviews

7. Non-Sulfonylurea Insulin Secretagogues

Non-Sulfonylurea Insulin Secretagogues Non-Sulfonylurea Insulin Secretagogues Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Non (...) -Sulfonylurea Insulin Secretagogues Non-Sulfonylurea Insulin Secretagogues Aka: Non-Sulfonylurea Insulin Secretagogues , Meglitinide , Repaglinide , Prandin , Nateglinide , Starlix From Related Chapters II. Mechanism secretogogue III. Indication Early Oral Agent Elevated postprandial Consider if only used intermittently pre-meal IV. Contraindications to sulfa V. Category VI. Mechanism Benzoic acid derivative Similar to Binds different sites from s Closes ATP sensitive K+ channels Results in secretion

2015 FP Notebook

8. Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)"

(Nesina Tablets) in type 2 diabetic patients who have had an inadequate response to hypoglycemic agents (e.g., insulin preparations or rapid-acting insulin secretagogues)* in addition to dietary/exercise therapy in daily medical practice. * Patients receiving these hypoglycemic agents (excluding α-glucosidase inhibitors, thiazolidines, sulfonylureas, and biguanides) were excluded from existing specified drug-use surveys for Nesina Tablets. Condition or disease Intervention/treatment Type 2 Diabetes (...) /therapies: • Use of one hypoglycemic agent such as insulin preparations and rapid-acting insulin secretagogues, excluding other types of hypoglycemic agents (e.g., α-glucosidase inhibitors, thiazolidines, sulfonylureas, and biguanides)*, in addition to dietary/exercise therapy * For use of Nesina Tablets in combination with these agents, a specified drug-use survey is currently ongoing. Exclusion Criteria: -Type 2 diabetic patients who meet any of the following criteria are excluded from this survey

2014 Clinical Trials

9. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials

) inhibitors, pioglitazone, agents that stimulate insulin secretion (secretagogues), and acarbose on blood lipids, compared with placebo. Searching MEDLINE and The Cochrane Library were searched, for publications in English, up to November 2011. Search terms were reported. Study selection Placebo randomised controlled trials (RCTs) reporting total endpoint cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides, for at least 200 patients (...) Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials Monami M, Vitale V, Ambrosio ML, Bartoli N

2012 DARE.

10. A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensific

s)/regimen: a. Biguanides (metformin at least 1500 mg or maximum tolerated dose documented in the subject medical record) b. Other OADs (at least half of the maximum approved dose according to local label or maximum tolerated dose as documented in subject medical record): i. Insulin secretagogues (SU and glinides) ii. Di-peptidyl-peptidase IV (DPP-4) inhibitors iii. α-glucosidase inhibitors iv. Sodium/glucose co-transporter 2 (SGLT-2) inhibitors v. Oral combination products (of the allowed (...) A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensific A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need

2016 Clinical Trials

11. Second Generation Sulfonylurea

or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See for financial assistance information. Ontology: Glyburide (C0017628) Definition (NCI) A highly protein bound, longer-acting second-generation sulfonylurea with antihyperglycemic activity. Glyburide, also called glibenclamide, is more likely to cause hypoglycemic (...) ; hypoglycemic used against non-insulin dependent diabetes mellitus; thought to act by increasing insulin receptor expression in target tissues. Concepts Pharmacologic Substance ( T121 ) , Organic Chemical ( T109 ) MSH SnomedCT 384978002 , 80870001 , 387466004 LNC LP14720-4, MTHU001812 English Glibenclamide , Glybenclamide , Benzamide, 5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxy- , glyburide , Glyburide , Gyburide , Glyburide (substance) , glyburide (medication

2018 FP Notebook

12. Sulfonylurea

Sulfonylurea Sulfonylurea Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Sulfonylurea Sulfonylurea Aka: Sulfonylurea , Insulin (...) Secretagogue From Related Chapters II. Background Discovered in 1940's when investigating antibiotics III. Mechanism Stimulates channel closure on pancreatic beta cell surface Results in release IV. Types (Listed for historical purposes only) (e.g. , ) (e.g. , ) Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Sulfonylurea." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip

2018 FP Notebook

13. Oral Insulin Secretagogues, Insulin, and Cancer Risk in Type 2 Diabetes Mellitus. (PubMed)

Oral Insulin Secretagogues, Insulin, and Cancer Risk in Type 2 Diabetes Mellitus. Hyperinsulinemia might be the mechanism leading to an increased cancer risk in patients with type 2 diabetes. The objective was to evaluate the association between oral insulin secretagogues, insulins, and cancer incidence.A total of 108,920 patients with newly diagnosed type 2 diabetes were identified from the Taiwan National Health Insurance claims database during the period from 1 January 2000 to 31 December (...) (OR, 1.97; 95% CI, 1.85-2.09) and glinides (OR, 1.16; 95% CI, 1.06-1.28). Significantly increased risks were found for first- and second-generation sulfonylureas (OR, 1.08; 95% CI, 1.01-1.15), but not for third-generation drug, glimepiride (OR, 1.00; 95% CI, 0.93-1.08). Use of insulin and glinides was associated with higher risks for liver, colorectal, lung, stomach, and pancreas cancer, whereas sulfonylurea was mainly associated with an increased risk of liver cancer.The results showed

Full Text available with Trip Pro

2012 Journal of Clinical Endocrinology and Metabolism

14. Insulin Degludec (Tresiba, Novo Nordisk A/S) for the Treatment of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks

of complications and note that lower goals are appropriate for patients who are able to reach them safely and easily. Higher goals should be considered for patients with comorbidities or who experience hypoglycemia. The guidelines recommend basal insulin used when sulfonylureas, rapid-acting insulin secretagogues, AG inhibitors, DPP-4 inhibitors, or TZD no longer result in glucose control in combination with metformin. NPH insulin, insulin glargine, insulin detemir, and biphasic insulin are recommended (...) Review DATE OF PUBLICATION: March 14, 2016 We would also like to thank Shanshan Liu, Elizabeth Russo, Matt Seidner, Patricia Synnott, and Karin Travers of ICER for their contributions to this report. ©Institute for Clinical and Economic Review, 2016 Page ii Final Report – Insulin Degludec About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders

2017 California Technology Assessment Forum

15. Effects of mitiglinide, a short-acting insulin secretagogue, on daily glycemic variability and oxidative stress markers in Japanese patients with type 2 diabetes mellitus. (PubMed)

Effects of mitiglinide, a short-acting insulin secretagogue, on daily glycemic variability and oxidative stress markers in Japanese patients with type 2 diabetes mellitus. The objective of this study was to clarify the effects of mitiglinide on daily glycemic variability and oxidative stress markers in outpatients with type 2 diabetes mellitus that is insufficiently controlled by diet and/or non-insulin secretagogues.We enrolled 24 patients with type 2 diabetes whose glycemic control had been

2013 Clinical drug investigation

16. A Comparative Study of the Effects of QS-M Needle Free Injector and Glargine Pen Subcutaneous Injection of Insulin Glargine on Insulin Use

, diabetic ketoacidosis or hyperosmolar coma. serious diabetic complications such as diabetic foot, diabetic nephropathy and so on; severe cardiovascular events occurred in the last 6 months. the application of hormone or immunosuppressant, or low immunity defect; the use of non steroidal anti-inflammatory drugs; the use of sulfonylureas and insulin secreting agents; a person with a history of cancer; a history of unstable or rapid progressive renal disease; an unstable history of major mental illness (...) of insulin glargine and also take one to three kinds of oral medicine (not including secretagogues) patients, daily insulin glargine total dose more than 12IU but <50IU, the use of insulin glargine than in January; the blood glucose in the fasting vein was in 5.0-9.0mmol/L; the letter of informed consent has been read and signed. Exclusion Criteria: there is conflict of interest with this research. blood glucose control is not good enough to participate in this study, such as repeated hypoglycemia

2018 Clinical Trials

17. Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliquaâ„¢) in Patients With Type 2 Diabetes Mellitus (T2DM)

: To demonstrate that the simple daily titration algorithm is non-inferior to the weekly titration algorithm according to Canadian labeling. Secondary Objective: To gain additional information on the efficacy and safety of using a simple patient-titration protocol for administration of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi). Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010 Phase 3 Detailed Description (...) allowed at inclusion are metformin, insulin secretagogues, dipeptidyl-peptidase-4 inhibitors (DPP4) inhibitors and SGLT2 inhibitors; with no change in OAD dose for at least 2 months prior to randomization Body mass index (BMI) between 20 kg/m2 and 40 kg/m2 inclusively Exclusion criteria: History of severe hypoglycemia or hypoglycemia unawareness History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening visit Current or previous (known intolerance to GLP-1s

2018 Clinical Trials

18. Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

) of OAD(s) for at least 90 days prior to screening (Visit 1). The OAD(s) include any of the following anti-diabetic drug(s)/regimen: Biguanides (metformin equal to or above 1500 mg or maximum tolerated dose documented in the subject medical record) Insulin secretagogues (sulfonylureas (SU) and glinides), Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), a-glucosidase inhibitors, Sodium-glucose co-transporter 2- inhibitors (SGLT2 Inhibitors ) (above or equal to half of the maximum approved dose (...) Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting

2016 Clinical Trials

19. Variations in tissue selectivity amongst insulin secretagogues: a systematic review. (PubMed)

Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Insulin secretagogues promote insulin release by binding to sulfonylurea receptors on pancreatic β-cells (SUR1). However, these drugs also bind to receptor isoforms on cardiac myocytes (SUR2A) and vascular smooth muscle (SUR2B). Binding to SUR2A/SUR2B may inhibit ischaemic preconditioning, an endogenous protective mechanism enabling cardiac tissue to survive periods of ischaemia. This study was designed (...) to identify insulin secretagogues that selectively bind to SUR1 when given at therapeutic doses.Using accepted systematic review methods, three electronic databases were searched from inception to 13 June 2011. Original studies measuring the half-maximal inhibitory concentration (IC(50)) for an insulin secretagogue on K(ATP) channels using standard electrophysiological techniques were included. Steady-state concentrations (C(SS)) were estimated from the usual oral dose and clearance values for each

2012 obesity & metabolism

20. Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Ages Eligible for Study: 20 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion criteria : Patient with type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year before the screening visit, receiving 1 or 2 OADs that can be Biguanide,Thiazolidinedione (TZD), -Alpha-glucosidase-inhibitor (alpha-GI),Sodium glucose co-transporter 2 (SGLT2) inhibitor,Sulfonylurea (SU),Rapid-acting insulin secretagogue (Glinide),diphenyl-peptidase -4 (...) Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>